SSGJ-612
SSGJ-612 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at HER2.
Overview
SSGJ-612 is a monoclonal antibody developed by Shenyang Sunshine Pharmaceutical. Its target is HER2. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07646626, plans to enrol 150 participants with primary completion expected 2027-06-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"SSGJ-612" OR ABSTRACT:"SSGJ-612") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SSGJ-612, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentCinrebafusp alfa
Shares HER2 and the tags pipeline, ctgov-ingest.
- TreatmentSSGJ-705
Shares HER2 and the tags pipeline, ctgov-ingest.
- TreatmentTQB2930
Shares HER2 and the tags pipeline, ctgov-ingest.
- TreatmentABSK061
Shares HER2 and the tags pipeline, ctgov-ingest.
- TreatmentGLSI-100
Shares HER2 and the tags pipeline, ctgov-ingest.
- TreatmentRPH-051
Shares HER2 and the tags pipeline, ctgov-ingest.
- TreatmentRO7771950
Shares HER2 and the tags pipeline, ctgov-ingest.
- TreatmentIAH0968
Shares HER2 and the tags pipeline, ctgov-ingest.